Many fixed dose combination drugs have been approved for diabetes, such as metformin and DPP4 inhibitors, DPP4 inhibitors and SGLT-2 inhibitors, etc. Adding a gut-restricted GPR40 agonist to the existing fixed dose combination drugs will unlikely cause additional DDI as it will not be absorbed and affect liver enzymes involved in drug metabolism. This evidence concerns the gene FFAR1 and diabetes mellitus.